Benzinga | Jul 29, 2021 04:01PM EDT

PTC Therapeutics Q2 EPS $(1.68) Beats $(1.82) Estimate, Sales $103.11M Miss $110.50M Estimate

PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(1.68) per share which beat the analyst consensus estimate of $(1.82) by 7.69 percent. This is a 35.88 percent increase over losses of $(2.62) per share from the same period last year. The company reported quarterly sales of $103.11 million which missed the analyst consensus estimate of $110.50 million by 6.69 percent. This is a 37.05 percent increase over sales of $75.24 million the same period last year.